Giuseppe Manfroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7279854/publications.pdf

Version: 2024-02-01

70 papers	1,928 citations	201575 27 h-index	289141 40 g-index
70 all docs	70 docs citations	70 times ranked	2570 citing authors

#	Article	IF	Citations
1	Broad-Spectrum Anti-Flavivirus Activity and Chemistry of Compounds Containing Sulfur and Oxygen Chalcogens. Current Medicinal Chemistry, 2023, 30, 2396-2420.	1.2	3
2	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Medicinal Chemistry Letters, 2022, 13, 855-864.	1.3	10
3	Virucidal Activity of the Pyridobenzothiazolone Derivative HeE1-17Y against Enveloped RNA Viruses. Viruses, 2022, 14, 1157.	1.5	4
4	Sustainable, three-component, one-pot procedure to obtain active anti-flavivirus agents. European Journal of Medicinal Chemistry, 2021, 210, 112992.	2.6	6
5	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. European Journal of Medicinal Chemistry, 2021, 209, 112944.	2.6	17
6	Pyridobenzothiazolones as anti-flavivirus agents: Impact on Zika virus. , 2021, , 349-358.		0
7	From Quinoline to Quinazolineâ€Based S. aureus NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search. ChemMedChem, 2021, 16, 3044-3059.	1.6	9
8	Targeting miRNA dysregulation with small molecules: the case of enoxacin. Future Medicinal Chemistry, 2021, 13, 1245-1248.	1.1	1
9	Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7037.	1.8	8
10	Broadâ€Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View. ChemMedChem, 2020, 15, 2391-2419.	1.6	25
11	Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs. Journal of Medicinal Chemistry, 2020, 63, 12275-12289.	2.9	20
12	Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. European Journal of Medicinal Chemistry, 2020, 201, 112420.	2.6	12
13	1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Molecules, 2020, 25, 1183.	1.7	23
14	Pyridobenzothiazolones Exert Potent Anti-Dengue Activity by Hampering Multiple Functions of NS5 Polymerase. ACS Medicinal Chemistry Letters, 2020, 11, 773-782.	1.3	28
15	C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 584-597.	2.5	13
16	Comprehensive response to Usutu virus following first isolation in blood donors in the Friuli Venezia Giulia region of Italy: Development of recombinant NS1-based serology and sensitivity to antiviral drugs. PLoS Neglected Tropical Diseases, 2020, 14, e0008156.	1.3	17
17	New Insights on KCa3.1 Channel Modulation. Current Pharmaceutical Design, 2020, 26, 2096-2101.	0.9	4
18	Discovery of potent p38Î± MAPK inhibitors through a funnel like workflow combining in silico screening and inÂvitro validation. European Journal of Medicinal Chemistry, 2019, 182, 111624.	2.6	17

#	Article	IF	Citations
19	Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. ACS Infectious Diseases, 2019, 5, 982-1000.	1.8	10
20	Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. Antiviral Research, 2019, 167, 6-12.	1.9	24
21	Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38Î± MAPK inhibitors. Biochemical and Biophysical Research Communications, 2019, 511, 579-586.	1.0	6
22	From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 55-74.	2.5	16
23	Design and Synthesis of WM5 Analogues as HIV-1 TAR RNA Binders. Open Medicinal Chemistry Journal, 2019, 13, 16-28.	0.9	2
24	Advantageous Use of Ionic Liquids for the Synthesis of Pharmaceutically Relevant Quinolones. European Journal of Organic Chemistry, 2018, 2018, 2977-2983.	1.2	10
25	A Comprehensive Structural Overview of p38Î± Mitogenâ€Activated Protein Kinase in Complex with ATPâ€Site and Nonâ€ATPâ€Site Binders. ChemMedChem, 2018, 13, 7-14.	1.6	20
26	Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry, 2018, 143, 1667-1676.	2.6	24
27	2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. Journal of Medicinal Chemistry, 2018, 61, 7827-7848.	2.9	46
28	Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position. European Journal of Medicinal Chemistry, 2018, 155, 428-433.	2.6	19
29	Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 1598-1604.	2.9	59
30	Searching for Novel Inhibitors of the S.â€...aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3â€Phenylâ€1,4â€benzothiazine Analogues. ChemMedChem, 2017, 12, 1293-1302.	1.6	28
31	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. European Journal of Medicinal Chemistry, 2017, 138, 128-139.	2.6	38
32	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. European Journal of Medicinal Chemistry, 2017, 140, 321-330.	2.6	28
33	Investigation on the effect of known potent S. aureus NorA efflux pump inhibitors on the staphylococcal biofilm formation. RSC Advances, 2017, 7, 37007-37014.	1.7	33
34	Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R againstEscherichia coli. PeerJ, 2017, 5, e3168.	0.9	38
35	Studies on Cycloheptathiopheneâ€3â€carboxamide Derivatives as Allosteric HIVâ€1 Ribonucleaseâ€H Inhibitors. ChemMedChem, 2016, 11, 1709-1720.	1.6	15
36	Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor. Antiviral Research, 2016, 134, 226-235.	1.9	49

#	Article	IF	Citations
37	Bicyclic octahydrocyclohepta[b]pyrrol-4(1 H)one derivatives as novel selective anti-hepatitis C virus agents. European Journal of Medicinal Chemistry, 2016, 122, 319-325.	2.6	6
38	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogenâ€Activated Protein Kinase Inhibitors. Chemical Biology and Drug Design, 2015, 86, 531-545.	1.5	14
39	Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium. ACS Infectious Diseases, 2015, 1, 593-603.	1.8	21
40	Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. European Journal of Medicinal Chemistry, 2015, 96, 250-258.	2.6	24
41	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Proteinâ€"Basic Protein 1 (PA-PB1) Subunits. Journal of Medicinal Chemistry, 2015, 58, 3830-3842.	2.9	81
42	A Comprehensive Structural Overview of p38Î± MAPK in Complex with Typeâ€…I Inhibitors. ChemMedChem, 2015, 10, 957-969.	1.6	17
43	Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. Journal of Chemical Information and Modeling, 2014, 54, 481-497.	2.5	16
44	New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 3247-3262.	2.9	35
45	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1952-1963.	2.9	43
46	Enantioresolution, stereochemical characterization and biological activity of a chiral large-conductance calcium-activated potassium channel opener. Journal of Chromatography A, 2014, 1363, 162-168.	1.8	20
47	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 4658-4666.	1.4	19
48	Ethyl 1,8-Naphthyridone-3-carboxylates Downregulate Human Papillomavirus-16 E6 and E7 Oncogene Expression. Journal of Medicinal Chemistry, 2014, 57, 5649-5663.	2.9	9
49	1,4-Benzothiazine ATP-Sensitive Potassium Channel Openers: Modifications at the C-2 and C-6 Positions. Journal of Medicinal Chemistry, 2013, 56, 4718-4728.	2.9	20
50	Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. Journal of Medicinal Chemistry, 2013, 56, 10118-10131.	2.9	51
51	Computerâ€Aided Design, Synthesis and Validation of 2â€Phenylquinazolinone Fragments as CDK9 Inhibitors with Antiâ€HIVâ€1 Tatâ€Mediated Transcription Activity. ChemMedChem, 2013, 8, 1941-1953.	1.6	32
52	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. Journal of Medicinal Chemistry, 2013, 56, 2270-2282.	2.9	40
53	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. Journal of Medicinal Chemistry, 2013, 56, 4975-4989.	2.9	51
54	Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. International Journal of Pharmaceutics, 2013, 454, 316-323.	2.6	45

#	Article	IF	Citations
55	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 3568-3572.	2.9	82
56	Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase. Bioorganic and Medicinal Chemistry, 2012, 20, 866-876.	1.4	41
57	Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Medicinal Chemistry, 2011, 3, 1027-1055.	1.1	39
58	Discovery of Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus. Journal of Medicinal Chemistry, 2011, 54, 354-365.	2.9	67
59	Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the S. aureus NorA Efflux Pump. Journal of Medicinal Chemistry, 2011, 54, 5722-5736.	2.9	102
60	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6â€Naphthyridone Derivative with Potent and Selective Antiâ€HIV Activity. ChemMedChem, 2011, 6, 1249-1257.	1.6	30
61	N-Benzoyl-N-methylsulfonyl anthranilates: unexpected cyclization reaction to 4-alkoxy-2,1-benzothiazines. Arkivoc, 2011, 2011, 165-176.	0.3	5
62	Studies of Antiâ€HIV Transcription Inhibitor Quinolones: Identification of Potent N1â€Vinyl Derivatives. ChemMedChem, 2010, 5, 1880-1892.	1.6	26
63	Synthesis of 2-(Arylamino)ethanethiols via Lewis Acid Catalyzed Aminolysis of 2,2-Dimethylthiirane as Precursors of the 1,4-Benzothiazine Nucleus. Synthesis, 2009, 2009, 1513-1519.	1.2	2
64	Studies on anti-HIV quinolones: New insights on the C-6 position. Bioorganic and Medicinal Chemistry, 2009, 17, 667-674.	1.4	32
65	Synthesis and biological evaluation of 2-phenylquinolones targeted at Tat/TAR recognition. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 714-717.	1.0	21
66	Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. Journal of Medicinal Chemistry, 2009, 52, 3354-3365.	2.9	54
67	Structureâ^'Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. Journal of Medicinal Chemistry, 2008, 51, 5454-5458.	2.9	56
68	Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca2+-Activated Potassium Channel Openers. Journal of Medicinal Chemistry, 2008, 51, 5085-5092.	2.9	29
69	Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents1. Journal of Medicinal Chemistry, 2006, 49, 2621-2627.	2.9	71
70	Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. Journal of Medicinal Chemistry, 2004, 47, 5567-5578.	2.9	45